The road to Boston: Venture Leaders Biotech 2024 kick-off their roadshow at Swiss Biotech Day
The ten Venture Leaders Biotech made a strong impression at the Swiss Biotech Day in Basel, presenting their innovations and building a strong team spirit ahead of the awaited investor and business development roadshow in Boston in May.
The Swiss Biotech Day is a premier biotechnology conference in Europe, attracting entrepreneurs, investors, researchers, policymakers, and industry experts from the global life sciences community. With over 1,800 senior experts, more than 100 exhibitors, and an international delegation present in the conference's Global Village, the congress promotes global connectivity of biotech innovators and offers an ideal space to explore trends in R&D, manufacturing, data management, AI, and fundraising opportunities.According to the Swiss Biotech Association, the life sciences sector (pharmaceuticals, vitamins, and diagnostics) represents the largest and most dynamic export industry in Switzerland: In 2022, it accounted for 39% of total Swiss exports and added a record CHF 109.6 billion (+0.6% over 2021) to the foreign export trade. In the twenty years from 2002 to 2022, its contribution expanded by 255%. The Venture Leaders Biotech program contributes to the enduring strength and vitality of such a sector.
In the morning, the Venture Leaders participated in a workshop with program partner VISCHER about the legal aspects of funding a Biotech startup. Later, they took the stage to introduce their breakthroughs to the audience and Maria van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs, were voted team captains.
Venture Leaders Biotech 2024 at the kick-off at Swiss Biotech Day: David Pejoski (Adoram Therapeutics), Kevin Yim (EVIIVE), Gabriel Liguori (TissueLabs), Maria van Dongen (Allegria Therapeutics), Bryan Porcello (KYLYS AESTHETICS), Peter Schiemann (Ymmunobio), David Roura Padrosa (inSEIT), Arin Ghasparian (Shape Biopharmaceuticals), and Ian Metcalfe (Well Science), missing on the picture David Klein Cerrejon (OBaris)
The Venture Leaders Biotech team is following in the footsteps of Alentis, which announced a USD 105 million funding round, lino biotech, which participated in the Venture Leaders Biotech program in 2022 and was acquired by the German biomedical company Miltenyi Biotec, and IsoSpec Analytics, which recently raised USD 1.9 million in Pre-Seed Funding. Other renowned alums include Covagen (acquired by Johnson & Johnson), Versantis (acquired by Genfit), SimplicityBio (acquired by Precision for Medicine), and AMAL Therapeutics (acquired by Boehringer Ingelheim)."The whole team is thrilled to be at the kick-off at the Swiss Biotech Day. With a fantastic team and an incredible event, we're eager to make a real impact in the US. Grateful for the chance to represent Switzerland and Venture Leaders Biotech," commented Ian Metcalfe, CEO of BlossomUp.
Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex in Boston and supported by Debiopharm, EPFL, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, Novartis, Swiss Biotech Association, and VISCHER.
Follow the entrepreneurs and the Venture Leaders Biotech roadshow on social media using the hashtag #VLeadersBiotech or on www.venture-leaders.ch/biotech.
Learn more about the Venture Leaders Biotech 2024:
Adoram Therapeutics SA: Multi-asset pre-clinical stage Biotech startup
Adoram Therapeutics is a spin-off from the University of Geneva, discovering next generation small molecule therapies for cancer and inflammation based around GPCR drug targets, the largest class of r... Read more
Allegria Therapeutics AG: Therapeutics that modulate mast cell activity
Allegria Therapeutics is a Basel-based biopharma startup established in 2023 with a commitment to build a differentiated portfolio of therapeutic approaches around biological targets that modulate mas... Read more
EVIIVE AG: Next-generation liquid biopsy solutions.
Our startup specializes in the cutting-edge field of extracellular vesicle (EV) biomarker discovery, utilizing single EV analysis and machine learning to revolutionize precision medicine. We provide a... Read more
inSEIT AG: Enzyme immobilization for green industrial production
inSEIT (integral Service for Enzyme Immobilization Technologies) offers services focused on the screening, application and scaling up of enzyme immobilization to ensure the practical implementation in... Read more
KYLYS AESTHETICS SA: Revolutionizing Skin Filling Science
KYLYS AESTHETICS offers a biocompatible hyaluronan-based and thermosensitive dermal filler that has the ability to form microgel structures in the tissue, resulting in a long-lasting effect and no mig... Read more
OBaris AG: Providing a painless alternative to injectable drugs.
Our unique platform aims at shifting the current paradigm from injectables to a simple, non-invasive formulation that enables safe and efficacious delivery of a variety of macromolecular drugs across ... Read more
Shape Biopharmaceuticals AG: A new class of immunotherapies based on nanoparticles.
At Shape, we're pioneering a breakthrough in healthcare with proprietary engineered SHAPEnano particles, leveraging the immune system of patients to produce therapeutic antibodies directly inside thei... Read more
TissueLabs SA: The platform for creating organs and tissues in the lab.
TissueLabs is dedicated to building the platform for creating organs and tissues in the lab. We provide biomaterials, equipment, and services to support tissue engineering and regenerative medicine. O... Read more
Well Science AG: Natural immune support against allergic rhinitis
Founded in Freienbach, Switzerland in 2022, with support from the Nestlé R&D accelerator and the Swiss incubator firm Stryber, Well Science AG is on a mission to develop innovations to change the cour... Read more
Ymmunobio AG: First in class oncology drugs for unmet need
Ymmunobio has identified a new tumor marker with superior properties: 1. It is present in at least 13 solid tumors 2. It has a prevalence of up to 98% in cancer patients 3. It is not expressed by n... Read more
Related articles
Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs
read more
EVIIVE: The Venture Leader Biotech developing the next-generation liquid biopsy solution
read more
TissueLabs: The Venture Leader Biotech fabricating lab-grown tissues for research and therapeutic applications
read more
Allegria Therapeutics secures USD 3.5 million Seed Financing to drive innovation in mast cell-mediated disease treatment
read more
Ymmunobio: The Venture Leader Biotech developing on first-in-class cancer therapies
read more
KYLYS AESTHETICS: The Venture Leader Biotech revolutionizing skin filling science
read more
Allegria Therapeutics: The Venture Leader Biotech modulating mast cell activity
read more
Adoram Therapeutics: The Venture Leaders Biotech creating new treatments for patients with solid tumors or immune-based diseases
read more